



Attorney Docket No. 46943-CIP2 (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: 09/990,586

Group Art Unit: 1644


FILED: November 21, 2001

Examiner: not yet assigned

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND
METHODS OF USE THEREOF

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 15, 2003.

By: 
Sharon Bizokas

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on Form PTO-1449, attached hereto. Copies of certain references cited therein are presently provided. Copies of other references were previously provided to the Office (see below) in the priority applications, and are thus not submitted herewith, although they may be provided at the request of the Commissioner.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. ☒ Patents, publications or other information marked with an asterisk (*) on the attached PTO-1449 were previously cited by or submitted to the USPTO in connection with U.S.S.N. 09/293,854 (now U.S. Patent No. 6,555,319) filed April 16, 1999 and/or U.S.S.N.: 09/814,806 (now U.S. Patent No. 5,986,065) filed March 10, 1997, to which the subject application claims the benefit of the earlier filing date. As such, copies of many of these references are not included herewith pursuant to 37 C.F.R. § 1.98(d).

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
or
b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining

APPLICANT: Jin-an JIAO, et al.
U.S.S.N.: 09/990,586
FILED: November 21, 2001
Page 4 of 4


information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$ 180.00 for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date: **December 15, 2003**


Jennifer K. Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748

Customer No. 21874



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	DOCKET NO: 46943-CIP2 (71758)	SERIAL NO.: 09/990,586
	APPLICANT(S): Jin-an JIAO, et al.	
	FILING DATE: November 21, 2001	GROUP NO.: 1644

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA*	5,223,427	6/29/93	Edgington	435	240.27	
	AB	5,986,065	11/1999	Wong	530	388.22	
	AC	5,437,864	8/1/95	Edgington et al.	424	145.1	11/16/92
	AD	6,274,142 B1	8/14/01	O'Brien et al.	424	145.1	06/07/95
	AE	5,589,173	12/31/96	O'Brien et al.	424	145.1	6/16/94
	AF*	5,552,300	9/3/96	Makrides et al.	435	69.1	
	AG*	5,216,132	6/1/93	Basi	530	387.3	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA*	EP 420,937 B1	10/91	Europe			
	BB	WO 96/40921	19/12/96	PCT			Yes
	BC*	WO 96/13593	5/9/96	PCT			Yes
	BD*	WO 96/18105	6/13/96	PCT			Yes
	BE*	WO 91/18019	11/28/91	PCT			Yes

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	CA*	Rao et al., <i>Thrombosis Research</i> , 56:109-118 (1989).
	CB*	Fiore et al., <i>Blood</i> , 80(12):3127-3134 (1992).
	CC*	Clarke et al., <i>The Journal of Immunology</i> , 145:2286-96 (1990).
	CD*	Ragni et al., <i>Circulation</i> , 93:1913-1918 (1996).
	CE	Eric Camerer, et al., "Tissue Factor – And Factor X-Dependent Activation Of Protease-Activated Receptor 2 By Factor Vlla", May 9, 2000, <i>PNAS</i> , Vol. 97, No. 10, pages 5255-5260.
	CF	W. Ruf, et al. "Tissue Factor Signaling", (1999) <i>Thrombosis and Haemostasis</i> , 82(2), pages 175-182.
	CG	V. Ollivier, et al. "Tissue Factor-Dependent Vascular Endothelial Growth Factor Production By Human Fibroblasts In Response To Activated Factor VII", April 15, 1998, <i>Blood</i> , Vol. 91, No. 8, pp. 2698-2703.



FORM PTO-1449		DOCKET NO: 46943-CIP2 (71758)	SERIAL NO.: 09/990,586
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Jin-an JIAO, et al.	
		FILING DATE: November 21, 2001	GROUP NO.: 1644
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CH	M. T. Wiiger, et al. "Effects Of Binding Of Ligand (FV11a) To Induced Tissue Factor In Human Endothelial Cells", (2000), <i>Thrombosis Research</i> , 98, pages 311-321.		
CI	W. Konigsberg, et al. "The TF:VIIa Complex: Clinical Significance, Structure-Function Relationships And Its Role In Signaling And Metastasis", <i>Thrombosis Haemostasis</i> , (2001), 86, pages 757-771.		
CJ	M. Riewald, et al. "Mechanistic Coupling Of Protease Signaling And Initiation Of Coagulation By Tissue Factor", July 3, 2001, <i>PNAS</i> , Vol. 98, No. 14, pages 7742-7747.		
CK	B. M. Mueller, et al. "Expression Of Tissue Factor By Melanoma Cells Promote Efficient Hematogenous Metastasis", December 1992, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 11832-11836.		
CL	Poster Presentation Experimental Biology 2001, March 31 – April 4, 2001, Orlando, Florida Anti-Tissue Factor Antibodies.		
CM	Francis, J. L., et al. (2002) Sem. in Thrombosis and Haemostasis, Vol. 28:1, pp. 29-38.		
CN	Amirkhosravi, A., et al. (2001), Suppl. To J. of Thrombosis and Haemostasis Abstract:OC1021.		
CO*	S. Ward, <i>Communications</i> , pp. 885-890 (1992).		
CP*	C. Schlueter et al., <i>J. Mol. Biol.</i> , 256:859-869 (1996).		
CQ*	T. Onda et al., <i>Molecular Immunology</i> , 32(17-18):1387-1397 (1995).		
CR*	J. Novotny et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88:8646-8650 (1991).		
CS*	C. Wulfig et al., <i>J. Mol. Biol.</i> , 242:655-669 (1994).		
CT*	I. Kurucz et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:3830-3834 (1993).		
CU*	S. Parmley et al., <i>Gene</i> , 73:305-318 (1988).		
CV*	G. Smith et al., <i>Methods in Enzymology</i> , 217:228-257 (1993).		
CW*	C. Chothia et al., <i>The EMBO Journal</i> , 7(12):3745-3755 (1988).		
CX*	W. Soo Hoo et al., <i>Proc. Natl. Acad. Sci. USA</i> , 89:4759-4763 (1992).		
CY*	E. Ward, <i>Scand. J. Immunol.</i> , 34:215-220 (1991).		
CZ*	A. Lin et al., <i>Science</i> , 249:677-679 (1990).		
DA*	C. Gregoire et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88:8077-8081 (1991).		
DB*	N. Gasciogne et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84:2936-2940 (1987).		
DC*	R. Mariuzza et al., <i>The Journal of Biological</i> , 264(13):7310-7316 (1989).		
DE*	J. Kappler et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91:8462-8466 (1994).		
DF*	George et al., <i>Macromolecular Sequencing and Synthesis</i> , Alan Riss, pp. 127-149 (1988).		



FORM PTO-1449		DOCKET NO: 46943-CIP2 (71758)	SERIAL NO.: 09/990,586
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Jin-an JIAO, et al.	
		FILING DATE: November 21, 2001	GROUP NO.: 1644
	DG*	Groves et al., <i>Hybridoma</i> , 6(1):71-76 (1987).	
	DH*	Illustrated Dictionary of Immunology, Cruse et al., CRC Press (1995).	
	DI*	Morrison, <i>Ann. Rev. Immunol.</i> , 10:239-265 (1992).	
EXAMINER:			DATE:

BOS2_349281.1